General
Ezri Care Artificial Tears Recall
The Centers for Disease Control and Prevention (CDC) is investigating multiple reports of carbapenem-resistant Pseudomonas aeruginosa (CRPA) eye infections, which may have a common source. A total of 13 cases of CRPA eye infections from four states (including 11 cases associated with 2 clusters in 2 states) have been reported to CDC; specimen collection dates range from May 17 to December 13, 2022. Among the 11 patients for which information is available, infection types included keratitis and endophthalmitis.
NMHAN CDC Advisory: Prioritize Antivirals for Influenza
Drug Shortage Alert- Pediatric Antipyretics and Amoxicilin
CDC and FDA Authorize COVID19 Bivalent Vaccine for Youngest Children
COVID-19 Therapeutics Update: Bebtelovimab & Evusheld Pause
Increased Respiratory Activity - 2022-23 Season
Congenital Syphilis - 10/05/2022
First confirmed Candida auriscase in NM - 10/05/2022
Adverse Child Experiences in New Mexico
The Centers for Disease Control and Prevention (CDC) is issuing this Health Alert Network (HAN) Health Advisory about a recently confirmed outbreak of Ebola virus disease (EVD) in Uganda caused by Sudan virus (species Sudan ebolavirus) to summarize CDC’s recommendations for U.S. public health departments and clinicians, case identification and testing, and clinical laboratory biosafety considerations.
UNM Capacity - 09/16/2022
As of the end of August 2022, national sentinel surveillance sites for respiratory pathogens are reporting increases in pediatric hospitalizations of patients with severe respiratory illness who also tested positive for rhinovirus (RV) and/or enterovirus (EV).
RV-EV Respiratory Illness
Reccomendations for HAN Flu Vaccinations
On August 31, 2022, the FDA authorized emergency use of new bivalent formulations of both the Moderna COVID-19 and the Pfizer-BioNTech COVID-19 Vaccines for use as a single booster dose at least two months following primary or booster vaccination.
As of August 8, 2022, the Centers for Disease Control and Prevention (CDC) and state and local public health departments are reporting 8934 confirmed and probable cases of monkeypox in the United States across 49 states, Washington D.C., and Puerto Rico
Paxlovid is a highly effective treatment against COVID-19. In clinical trials, Paxlovid was shown to have an 88% reduction in hospitalization and death.
Monkeypox Virus Infection in the United States and Other Non-endemic Countries - 07/08/2022
New Mexico Department of Health (NMDOH) Marks the End of the 2021-2022 Influenza Season